Why are cancer drug prices rising?
Analysis of revenue trends and the number of patients treated with targeted oncology therapies reveals that the ability of pharmaceutical companies to determine their own prices may not underlie rising cancer therapy costs.
Please sign in or register for FREE
Sign in to The Evidence Base
Did you know?
Your The Evidence Base™ account also gives you access to communities on regenerative medicine, real-world evidence and drug discovery. Find out more>>